Your browser doesn't support javascript.
loading
Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.
Strafella, Antonio P; Bohnen, Nicolaas I; Perlmutter, Joel S; Eidelberg, David; Pavese, Nicola; Van Eimeren, Thilo; Piccini, Paola; Politis, Marios; Thobois, Stephane; Ceravolo, Roberto; Higuchi, Makoto; Kaasinen, Valtteri; Masellis, Mario; Peralta, M Cecilia; Obeso, Ignacio; Pineda-Pardo, Jose Ángel; Cilia, Roberto; Ballanger, Benedicte; Niethammer, Martin; Stoessl, Jon A.
Afiliação
  • Strafella AP; Morton and Gloria Shulman Movement Disorder Unit & E.J. Safra Parkinson Disease Program, Neurology Div/Dept. Medicine, Toronto Western Hospital, UHN; Krembil Research Institute, UHN; Research Imaging Centre, Campbell Family Mental Health Research Institute, CAMH, University of Toronto, Ontario,
  • Bohnen NI; University of Michigan & Veterans Administration Medical Center, Ann Arbor, Michigan, USA.
  • Perlmutter JS; Neurology, Radiology, Neuroscience, Physical Therapy & Occupational Therapy, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Eidelberg D; Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York, USA.
  • Pavese N; Newcastle Magnetic Resonance Centre & Positron Emission Tomography Centre, Newcastle University, Campus for Ageing & Vitality, Newcastle upon Tyne, United Kingdom.
  • Van Eimeren T; Multimodal Neuroimaging Group-Department of Nuclear Medicine Department of Neurology-University of Cologne, Institute of Neuroscience and Medicine, Jülich Research Center, German Center for Neurodegenerative Diseases (DZNE), Germany.
  • Piccini P; Neurology Imaging Unit, Centre of Neuroinflammation and Neurodegeneration, Division of Brain Sciences, Hammersmith Campus, Imperial College London, United Kingdom.
  • Politis M; Neurodegeneration Imaging Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
  • Thobois S; Hospices Civils de Lyon, Hopital Neurologique Pierre Wertheimer, Université Lyon 1; CNRS, Centre de Neurosciences Cognitives, UMR, 5229, Lyon, France.
  • Ceravolo R; Department of Clinical and Experimental Medicine, Movement Disorders and Parkinson Center, University of Pisa, Italy.
  • Higuchi M; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
  • Kaasinen V; Division of Clinical Neurosciences, Turku University Hospital; Department of Neurology, University of Turku; Turku PET Centre, University of Turku, Turku, Finland.
  • Masellis M; Cognitive & Movement Disorders Clinic, Sunnybrook Health Sciences Centre; Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.
  • Peralta MC; Movement Disorder and Parkinson's Disease Program, CEMIC University Hospital, Buenos, Aires, Argentina.
  • Obeso I; Centro Integral de Neurociencias (CINAC), Hospitales Madrid Puerta del Sur & Centro de Investigación Biomédica en Red, Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • Pineda-Pardo JÁ; Centro Integral de Neurociencias (CINAC), Hospitales Madrid Puerta del Sur & Centro de Investigación Biomédica en Red, Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • Cilia R; Parkinson Institute, ASST Gaetano Pini-CTO, Milan, Italy.
  • Ballanger B; INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, Neuroplasticity & Neuropathology of Olfactory Perception Team, University Lyon, France.
  • Niethammer M; Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, New York, USA.
  • Stoessl JA; Pacific Parkinson's Research Centre & National Parkinson Foundation Centre of Excellence, University of British Columbia & Vancouver Coastal Health, Vancouver, British, Columbia, Canada.
Mov Disord ; 32(2): 181-192, 2017 02.
Article em En | MEDLINE | ID: mdl-28150432
Molecular imaging has proven to be a powerful tool for investigation of parkinsonian disorders. One current challenge is to identify biomarkers of early changes that may predict the clinical trajectory of parkinsonian disorders. Exciting new tracer developments hold the potential for in vivo markers of underlying pathology. Herein, we provide an overview of molecular imaging advances and how these approaches help us to understand PD and atypical parkinsonisms. © 2016 International Parkinson and Movement Disorder Society.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Transtornos Parkinsonianos / Imagem Molecular Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Transtornos Parkinsonianos / Imagem Molecular Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article